Please login to the form below

Not currently logged in
Email:
Password:

Cipla appoints Novartis’ Subhanu Saxena as CEO

Was previously head of global product strategy and commercialisation at Swiss pharma firm

Subhanu Saxena has left Novartis to join India-based generics company Cipla as its new CEO.

Saxena was previously head of global product strategy and commercialisation at Novartis, where he was also part of the Swiss pharma giant's executive committee, and will take up his new position from February 1, 2013.

Prior to this most recent position at Novartis, Saxena was CEO and country president of Novartis UK.

He also has wide non-healthcare experience, working with companies such as Citicorp, the Boston Consulting Group and PepsiCo across markets in Europe, North America, Africa and Asia.

Cipla's chair Dr Yusuf Hamied said: “We are delighted to have found such a good match for Cipla in Subhanu. Cipla has a strong vision for the future. I am confident Subhanu will build on Cipla's core values to deliver the next phase of growth, competitiveness and return on shareholder value.”

Saxena joins at a time of growth for Cipla, with the company recently announcing plans to expand its footprint in Africa.

Cipla has also been busy challenging big pharma patents, and in September won a four-year battle to market its own version of Roche's cancer drug Tarceva (erlotinib). The verdict followed another recent win, that this time saw it granted permission to market a generic version of Pfizer's Sutent (sunitinib malate) after challenging the drug's patent.

26th November 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics